HIGHLIGHTS
- who: David Standing and colleagues from the Malades, France Washington University in StLouis have published the article: Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies, in the Journal: (JOURNAL)
- what: The authors demonstrate that Penfluridol binds to the PRLR ICD, and potently inhibits PRL: PRLR signaling that results in the inhibition of PDAC growth.
- future: Antibody based therapies may have significant potential for use in the future though further study and designs are required to fully assess their prospective use.
SUMMARY
In preclinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.